Buyer for cardiometabolic disease CRO in Europe

Company to buy

• Size: Medium business
• Sales: 20 – 50 million EUR
• Location: Europe
• Reason for acquisition: The management wants to expand their business in Europe
• #CFIE PHB244

Overview of buyer for cardiometabolic disease CRO in Europe

This is a leading contract research organization (CRO) with a rich history of supporting the development and execution of clinical trials. Founded more than 15 years ago in Central Europe, the company has grown to become a global player in the industry. Notably, it is known for its scientific expertise, operational excellence, and focus on specific therapeutic areas.

Profile (strategy) of buyer for cardiometabolic disease CRO in Europe

Essentially, the company’s story began with a team of passionate scientists and clinical trial experts who envisioned a CRO that would bridge the gap between academia and industry. Chiefly, they believed in the power of clinical research to improve human health. Also, they were committed to developing and delivering high-quality trials that would make a difference.

Subsequently, the company’s early years were marked by rapid growth, fueled by a strong reputation for quality and a dedication to client satisfaction. Then, the company quickly established itself as a leader in the field of central nervous system (CNS) trials. Soon after, it expanded its expertise to include other therapeutic areas such as cardiometabolic diseases infectious diseases, and vaccines.

Now, the company offers tailor-made full-service CRO and end-to-end site management organization (SMO) capabilities. At the same time, they cover global late-stage clinical drug trials with a strong focus on phases II, III, and IV, investigator-initiated trials, and observational real-world evidence studies.

Overall, the company’s expertise is particularly renowned and scientifically recognized in 3 main therapeutic areas:

– Central Nervous System (CNS) diseases: Alzheimer’s, amyotrophic lateral sclerosis (ALS), hearing loss, and epilepsy
– Infectious diseases and vaccines: Therapeutics and vaccine trials (e.g. pneumonia, influenza, COVID-19) with a specific focus on respiratory syncytial virus (RSV)
– Cardiometabolic diseases: Dyslipidemia and nonalcoholic steatohepatitis (NASH), etc.

Activities and products of suitable targets

Currently, the buyer is seeking a CRO in the field of cardiometabolic disease research. The buyer, renowned for its expertise in central nervous system (CNS) trials, is actively seeking a strategic acquisition in the cardiometabolic space. Now, this move signifies a bold ambition to solidify its position as a dominant player in the European clinical trial landscape.

Cardiometabolic diseases, encompassing diabetes, heart disease, and obesity, represent a massive and rapidly growing healthcare challenge. With an aging population and increasingly sedentary lifestyles, the demand for effective treatments and preventative measures is skyrocketing. Recognizing this immense potential, the buyer is strategically positioning itself to capitalize on this market shift.

Companies with strong track records in cardiovascular and metabolic research, coupled with complementary geographical footprints, are likely to be at the forefront of consideration.

Highlights

• Powerful and successful CRO approach leveraging demonstrated scientific expertise
• Unique know-how in multiple therapeutic areas driving a secured and balanced business model offering reliable business visibility
• Streamlined organization led by a seasoned and recognized team with historic experience in the CRO industry

More information on this buyer for cardiometabolic disease CRO in Europe

Please get in touch if you are interested in learning more about this buyer for cardiometabolic disease CRO in Europe. For more cro companies for sale please visit the section cro companies for sale. For other cro buyers, please visit the section cro companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.